BAP1 and renal cell carcinoma: The impact of DDR alterations on RCC is the premise of an ongoing clinical trial examining whether the poly ADP ribose polymerase inhibitor (PARPi) olarapib has antitumor activity in RCC harboring BAP1 or DDR mutations (NCT03786796).